Plain-English translation of NCT06976216 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called + to see if it can help improve memory and thinking skills in people with mild to moderate Alzheimer's disease. About 586 people will participate, and half will receive the new medication while the other half receive a placebo (a pill with no active ingredient). Researchers will track how well the medication works and whether it's safe.
Current treatments for Alzheimer's help some people but don't work well enough for everyone, and they can have side effects. This medication is being tested as a potential new option to help slow down memory loss and thinking problems in the early and middle stages of the disease.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic regularly to receive either the new medication or a placebo, and your caregiver would attend appointments with you. The study team will perform memory and thinking tests, ask questions about how you're doing, and monitor your health throughout the study. Your caregiver plays an important role in helping track how you're feeling and making sure you take the medication as prescribed.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
United States